Would Warren Buffett buy CSL shares?

Would the Sage from Omaha be interested in Australia's fallen giant?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Warren Buffett has been one of the world's greatest investors over the last several decades, helping Berkshire Hathaway (NYSE: BRK.B) become of the largest businesses in the world. Would such a great investor be interested in CSL Ltd (ASX: CSL) shares today?

Berkshire Hathaway has invested in a variety of industries over the years, including railroads, banks, Apple (NASDAQ: AAPL), insurance, oil and gas, soft drink, and so on. There's nothing to say that Berkshire Hathaway wouldn't be open to buying shares in a biotech company.

Let's look at what Warren Buffett might think of CSL shares.

a smiling picture of legendary US investment guru Warren Buffett.

Image source: Motley Fool Editorial

Is CSL a wonderful company?

There have been few businesses on the ASX that have expanded as much internationally as CSL over the last 20 years. It has been a great Australian success story.

However, the CSL share price has suffered a big decline in the past year, falling by around 50%. The market doesn't seem to think as much of the business as before.

Are the current difficult conditions CSL is facing temporary or is this now a permanent, lower growth environment for the company? You'd need a crystal ball to truly know the answer to that question.

But, when it comes to market confidence, Warren Buffett has said some potentially very useful advice in the past. For example, he has said generally about markets:

Be fearful when others are greedy, and greedy when others are fearful.

By that logic, investors may have been too fearful about the CSL share price earlier this year. But the CSL share price has risen by around 33% since the 2026 low in June – it's not as cheap as it was, even though it has fallen heavily over the longer term.

Warren Buffett has also suggested that it's better to buy a wonderful company at a fair price than a fair company at a wonderful price.

Before 2025, I think most investors would have been happy to describe CSL as a wonderful company with its ability to grow its core business, create new products with research and development (R&D), and deliver rising profit.

Is CSL still a wonderful company? The market doesn't seem convinced.

Warren Buffett's Circle of competence

For me, what could be the deciding factor in whether Warren Buffett would buy CSL shares is what he likes to call a circle of competence.

In other words, he only invests in businesses that he understands. That's why he famously avoided various technology businesses over the years. It's important to understand the potential gains, the competitive pressures and risks.

I think that same investment thought process would mean Buffett would be hesitant to invest in CSL – biotechnology is a difficult industry to understand, and it may be challenging to get to grips with how the research and development (R&D) pipeline could play out and what the financial rewards could be. Therefore, there are other ASX shares that I think Warren Buffett would be more interested in.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Apple, Berkshire Hathaway, and CSL. The Motley Fool Australia has recommended Apple, Berkshire Hathaway, and CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Six smiling health workers pose for a selfie.
Healthcare Shares

4DMedical share price rises as FY26 revenue climbs, losses moderate

4DMedical lifted revenue 21% and improved its adjusted net loss for FY26, while investing in new AI-driven medical imaging solutions.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Imricor Medical Systems and Philips launch MR-guided cardiac interventions lab

Imricor Medical Systems has teamed up with Philips to launch a new MR-guided cardiac interventions lab, targeting broader clinical adoption.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Why now is the time to buy low on these ASX healthcare shares with up to 84% upside

These two stocks have big upside.

Read more »

Silver dice with buy and sell written on them on top of stock market charts.
Healthcare Shares

CSL shares have surged 49%: Are brokers finally turning bullish?

CSL’s recovery is gathering pace, but has the share price already priced in the turnaround?

Read more »

a doctor wearing a white coat with a stethoscope around her neck stares out a window with her hand to the side of her face as though in deep thought.
Healthcare Shares

Clarity Pharmaceuticals FY26 earnings: Revenue jumps, losses widen as clinical pipeline progresses

Clarity Pharmaceuticals reported strong FY26 revenue growth, a wider loss, and progress towards commercialisation of its radiopharmaceutical pipeline.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Clinuvel Pharmaceuticals posts 10th consecutive profit and maintains dividend

Clinuvel Pharmaceuticals reported its tenth straight profit, rising cash reserves, and steady dividend for FY2026.

Read more »

Man and woman sitting at table with the man looking a bit puzzled at his laptop.
Healthcare Shares

Should I buy CSL shares before the end of August?

I think the company's earnings outlook is starting to look more encouraging.

Read more »

Female pharmacist smiles with a digital tablet.
Earnings Results

Sigma Healthcare FY26 earnings: Record profit as Chemist Warehouse merger delivers growth

The company reported double-digit revenue growth.

Read more »